346: Zealand's obesity strategy and Immunovant's curious development plan
The Readout Loud
Navigating Gene Therapy Controversies
This chapter explores a company's controversial decision to withhold their first-generation product while also addressing the serious implications of a teenager's death linked to a gene therapy for Duchenne muscular dystrophy. It raises urgent questions regarding the regulatory landscape, safety concerns, and the complexities of administering treatments to vulnerable patients.
00:00
Transcript
Play full episode
Remember Everything You Learn from Podcasts
Save insights instantly, chat with episodes, and build lasting knowledge - all powered by AI.
